Literature DB >> 9243217

A comparison of two ophthalmic steroid-antibiotic combinations after cataract surgery.

J J van Endt1, H G Veraart, R Kramer, A G Janssen, P Sunder Raj.   

Abstract

We performed this prospective, randomised, investigator-masked, parallel-group study to compare Fluorometholone-Gentamicin eye drops with Maxitrol (dexamethasone, neomycin, polymyxin B) eye drops in the reduction of ocular bacterial flora and control of ocular inflammation after cataract surgery. One hundred and twelve (FML-Genta 54, Maxitrol 58) patients of both sexes undergoing cataract and posterior chamber lens implant surgery for visually disabling cataract were enrolled in the study and examined pre-operatively and post-operatively on days 1, 6-8 and 24-34. The baseline parameters were similar in the two study groups. The conjunctival bacterial colony count on day 6-8 post-operatively was significantly less on FML-Genta compared with Maxitrol (p = 0.033). There was no statistically significant difference between the two treatments in the degree of intra-ocular inflammation as assessed by flare and cells in the anterior chamber. Both treatments were judged to be equal in the global assessment of the success of therapy and local tolerance by the study patients and doctors. Fluorometholone-gentamicin eye drops were more effective than Maxitrol eye drops in the reduction of ocular bacterial flora while being as well-tolerated and as effective as Maxitrol in the control of ocular inflammation after cataract surgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243217     DOI: 10.1177/112067219700700204

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  7 in total

Review 1.  Locally administered ocular corticosteroids: benefits and risks.

Authors:  Charles N J McGhee; Simon Dean; Helen Danesh-Meyer
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  The comparative efficacy and safety of topical non-steroidal anti-inflammatory drugs for the treatment of anterior chamber inflammation after cataract surgery: a systematic review and network meta-analysis.

Authors:  Ping Duan; Yong Liu; Jiawen Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-27       Impact factor: 3.117

3.  Comparison of the anti-inflammatory effects of fluorometholone 0.1% combined with levofloxacin 0.5% and tobramycin/dexamethasone eye drops after cataract surgery.

Authors:  Pei-Qing Chen; Xue-Mei Han; Ya-Nan Zhu; Jia Xu
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

4.  Combined antibacterial and anti-inflammatory activity of a cationic disubstituted dexamethasone-spermine conjugate.

Authors:  Robert Bucki; Katarzyna Leszczynska; Fitzroy J Byfield; David E Fein; Esther Won; Katrina Cruz; Andrzej Namiot; Alina Kulakowska; Zbigniew Namiot; Paul B Savage; Scott L Diamond; Paul A Janmey
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

5.  Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial.

Authors:  Mauro Campos; Mariana Avila; Anelise Wallau; Cristina Muccioli; Ana Luisa Höfling-Lima; Rubens Belfort
Journal:  Clin Ophthalmol       Date:  2008-06

6.  Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK.

Authors:  Mauro Campos; Cristina Muccioli; João Bns Malta; Rafael A Gerade; André LA Salame; Rubens Belfort
Journal:  Clin Ophthalmol       Date:  2011-02-15

7.  Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components.

Authors:  Patrícia Abreu Ferreira da Cunha; Flavio Araujo Shinzato; Geraldine Trevisan Tecchio; Sarah La Porta Weber; Alexandre Brasil; Amaryllis Avakian
Journal:  Clinics (Sao Paulo)       Date:  2013-06       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.